The observed increased expression of RIP3 in conditions like MASH and ALD, as well as its impact on AKT signaling and VLDL secretion markers, highlights its significance in hepatic steatosis and metabolic disturbances. This evidence concerns the gene RIPK3 and Hepatic steatosis.